Bluebird bio adds a key process to pioneering gene therapy as it ramps up a pivotal PhIII
Bluebird bio believes it has developed a new process that will make a marked improvement in their pioneering gene therapy programs, promising to deliver a significant impact on patient outcomes in a newly-launched pivotal study for LentiGlobin.
Late last year, bluebird bio execs were forced to explain why the latest data on LentiGlobin had proved disappointing in a small set of sickle cell patients being tested. Instead of the cure that bluebird $BLUE was looking for, several patients experienced a less than optimal response in producing anti-sickling hemoglobin, which caused more than a few investors in the company to do a double take on the company’s prospects.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.